{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T23:16:49Z","timestamp":1792019809116,"version":"4.4.0"},"reference-count":50,"publisher":"The Endocrine Society","issue":"8","license":[{"start":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T00:00:00Z","timestamp":1720396800000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>The cardiovascular benefits of semaglutide are established; however, its effects on surrogate vascular markers and liver function are not known.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To investigate the effects of semaglutide on vascular, endothelial, and liver function in patients with type 2 diabetes (T2DM) and nonalcoholic fatty liver disease (NAFLD).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Overall, 75 consecutive subjects with T2DM and NAFLD were enrolled: 50 patients received semaglutide 1 mg (treatment group) and 25 patients received dipeptidyl peptidase 4 inhibitors (control group). All patients underwent a clinical, vascular, and hepatic examination with Fibroscan elastography at 4 and 12 months after inclusion in the study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Treatment with semaglutide resulted in a reduction of Controlled Attenuation Parameter (CAP) score, E fibrosis score, NAFLD fibrosis score, Fibrosis-4 (FIB-4) score and perfused boundary region (PBR) at 4 and at 12 months (P &amp;lt; .05), contrary to controls. Patients treated with semaglutide showed a greater decrease of central systolic blood pressure (SBP) (\u22126% vs \u22124%, P = .048 and \u221211% vs \u22129%, P = .039), augmentation index (AIx) (\u221259% vs \u221252%, P = .041 and \u221270% vs \u221257%, P = .022), and pulse wave velocity (PWV) (\u22126% vs \u22123.5%, P = .019 and \u221212% vs \u221210%, P = .036) at 4 and at 12 months, respectively. In all patients, \u0394PWV and \u0394PBR were correlated with a corresponding reduction of CAP, E fibrosis, NAFLD fibrosis, and FIB-4 scores.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Twelve-month treatment with semaglutide simultaneously improves arterial stiffness, endothelial function, and liver steatosis and fibrosis in patients with T2DM and NAFLD.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/jendso\/bvae122","type":"journal-article","created":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T09:42:50Z","timestamp":1720431770000},"source":"Crossref","is-referenced-by-count":17,"title":["Semaglutide Concurrently Improves Vascular and Liver Indices in Patients With Type 2 Diabetes and Fatty Liver Disease"],"prefix":"10.1210","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7813-5488","authenticated-orcid":false,"given":"Emmanouil","family":"Korakas","sequence":"first","affiliation":[{"name":"2nd Department of Internal Medicine Research Unit and Diabetes Centre Attikon Hospital, Medical School National and Kapodistrian University of Athens , 12462 Athens , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5829-7327","authenticated-orcid":false,"given":"Aikaterini","family":"Kountouri","sequence":"additional","affiliation":[{"name":"2nd Department of Internal Medicine Research Unit and Diabetes Centre Attikon Hospital, Medical School National and Kapodistrian University of Athens , 12462 Athens , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Pavlidis","sequence":"additional","affiliation":[{"name":"2nd Department of Cardiology Laboratory of Preventive Cardiology and Echocardiography Department Attikon Hospital, Medical School National and Kapodistrian University of Athens , 12462 Athens , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Oikonomou","sequence":"additional","affiliation":[{"name":"3rd Department of Cardiology, National and Kapodistrian University of Athens, Medical School, Sotiria Chest Disease Hospital , 11527 Athens , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2157-0814","authenticated-orcid":false,"given":"Emmanouil","family":"Vrentzos","sequence":"additional","affiliation":[{"name":"Rheumatology and Clinical Immunology Unit, 4th Department of Internal Medicine, Attikon University Hospital, Joint Rheumatology Program, National and Kapodistrian University of Athens Medical School , 12462 Athens , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Michalopoulou","sequence":"additional","affiliation":[{"name":"2nd Department of Cardiology Laboratory of Preventive Cardiology and Echocardiography Department Attikon Hospital, Medical School National and Kapodistrian University of Athens , 12462 Athens , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki","family":"Tsigkou","sequence":"additional","affiliation":[{"name":"3rd Department of Cardiology, National and Kapodistrian University of Athens, Medical School, Sotiria Chest Disease Hospital , 11527 Athens , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1631-5210","authenticated-orcid":false,"given":"Konstantinos","family":"Katogiannis","sequence":"additional","affiliation":[{"name":"2nd Department of Cardiology Laboratory of Preventive Cardiology and Echocardiography Department Attikon Hospital, Medical School National and Kapodistrian University of Athens , 12462 Athens , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loukia","family":"Pliouta","sequence":"additional","affiliation":[{"name":"2nd Department of Internal Medicine Research Unit and Diabetes Centre Attikon Hospital, Medical School National and Kapodistrian University of Athens , 12462 Athens , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4209-1871","authenticated-orcid":false,"given":"Konstantinos","family":"Balampanis","sequence":"additional","affiliation":[{"name":"2nd Department of Internal Medicine Research Unit and Diabetes Centre Attikon Hospital, Medical School National and Kapodistrian University of Athens , 12462 Athens , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotirios","family":"Pililis","sequence":"additional","affiliation":[{"name":"2nd Department of Internal Medicine Research Unit and Diabetes Centre Attikon Hospital, Medical School National and Kapodistrian University of Athens , 12462 Athens , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5134-2401","authenticated-orcid":false,"given":"Konstantinos","family":"Malandris","sequence":"additional","affiliation":[{"name":"Clinical Research and Evidence-Based Medicine Unit, Aristotle University of Thessaloniki , 54124 Thessaloniki , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0221-4072","authenticated-orcid":false,"given":"Apostolos","family":"Tsapas","sequence":"additional","affiliation":[{"name":"Clinical Research and Evidence-Based Medicine Unit, Aristotle University of Thessaloniki , 54124 Thessaloniki , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7601-8870","authenticated-orcid":false,"given":"Gerasimos","family":"Siasos","sequence":"additional","affiliation":[{"name":"3rd Department of Cardiology, National and Kapodistrian University of Athens, Medical School, Sotiria Chest Disease Hospital , 11527 Athens , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8241-7886","authenticated-orcid":false,"given":"Ignatios","family":"Ikonomidis","sequence":"additional","affiliation":[{"name":"2nd Department of Cardiology Laboratory of Preventive Cardiology and Echocardiography Department Attikon Hospital, Medical School National and Kapodistrian University of Athens , 12462 Athens , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4620-4039","authenticated-orcid":false,"given":"Vaia","family":"Lambadiari","sequence":"additional","affiliation":[{"name":"2nd Department of Internal Medicine Research Unit and Diabetes Centre Attikon Hospital, Medical School National and Kapodistrian University of Athens , 12462 Athens , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2024,7,8]]},"reference":[{"issue":"9","key":"2024072604373988600_bvae122-B1","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"2024072604373988600_bvae122-B2","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3390\/pr9010135","article-title":"Non-alcoholic fatty liver disease: from pathogenesis to clinical impact","volume":"9","author":"Caturano","year":"2021","journal-title":"Processes"},{"issue":"5","key":"2024072604373988600_bvae122-B3","doi-asserted-by":"crossref","first-page":"287","DOI":"10.37349\/emed.2020.00019","article-title":"Nonalcoholic fatty liver disease and type 2 diabetes: pathophysiological mechanisms shared between the two faces of the same coin","volume":"1","author":"Acierno","year":"2020","journal-title":"Explor Med"},{"key":"2024072604373988600_bvae122-B4","doi-asserted-by":"crossref","first-page":"110027","DOI":"10.1016\/j.diabres.2022.110027","article-title":"Sex-specific differences in prevalence of nonalcoholic fatty liver disease in subjects with prediabetes and type 2 diabetes","volume":"190","author":"Succurro","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"issue":"6","key":"2024072604373988600_bvae122-B5","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease","volume":"64","author":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO)","year":"2016","journal-title":"J Hepatol"},{"issue":"16","key":"2024072604373988600_bvae122-B6","doi-asserted-by":"crossref","first-page":"4822","DOI":"10.3390\/molecules26164822","article-title":"What is the mechanism driving the reduction of cardiovascular events from glucagon-like peptide-1 receptor agonists? -A mini review","volume":"26","author":"Berndt","year":"2021","journal-title":"Molecules"},{"issue":"6","key":"2024072604373988600_bvae122-B7","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1177\/1741826711398179","article-title":"Methods for evaluating endothelial function: a position statement from the European Society of Cardiology working group on peripheral circulation","volume":"18","author":"Lekakis","year":"2011","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"issue":"10","key":"2024072604373988600_bvae122-B8","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/clc.20956","article-title":"Type 2 diabetes is associated with increased pulse wave velocity measured at different sites of the arterial system but not augmentation index in a Chinese population","volume":"34","author":"Zhang","year":"2011","journal-title":"Clin Cardiol"},{"issue":"11","key":"2024072604373988600_bvae122-B9","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1007\/s00592-023-02124-w","article-title":"GLP-1RAs and cardiovascular disease: is the endothelium a relevant platform?","volume":"60","author":"Menghini","year":"2023","journal-title":"Acta Diabetol"},{"issue":"7","key":"2024072604373988600_bvae122-B10","doi-asserted-by":"crossref","first-page":"983","DOI":"10.3390\/jcm8070983","article-title":"Effects of different antidiabetic medications on endothelial glycocalyx, myocardial function, and vascular function in type 2 diabetic patients: one year follow-up study","volume":"8","author":"Lambadiari","year":"2019","journal-title":"J Clin Med"},{"issue":"1","key":"2024072604373988600_bvae122-B11","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12933-017-0646-z","article-title":"Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetes","volume":"17","author":"Lambadiari","year":"2018","journal-title":"Cardiovasc Diabetol"},{"issue":"9","key":"2024072604373988600_bvae122-B12","doi-asserted-by":"crossref","first-page":"e015716","DOI":"10.1161\/JAHA.119.015716","article-title":"Effects of glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter-2 inhibitors, and their combination on endothelial glycocalyx, arterial function, and myocardial work index in patients with type 2 diabetes mellitus after 12-month treatment","volume":"9","author":"Ikonomidis","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"2024072604373988600_bvae122-B13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-020-01183-5","article-title":"Efficacy of dulaglutide on vascular health indexes in subjects with type 2 diabetes: a randomized trial","volume":"20","author":"Tuttolomondo","year":"2021","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"2024072604373988600_bvae122-B14","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.3390\/ijms24021703","article-title":"GLP-1 receptor agonists in non-alcoholic fatty liver disease: current evidence and future perspectives","volume":"24","author":"Nevola","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"11","key":"2024072604373988600_bvae122-B15","doi-asserted-by":"crossref","first-page":"9324","DOI":"10.3390\/ijms24119324","article-title":"Therapeutic mechanisms and clinical effects of glucagon-like peptide 1 receptor agonists in nonalcoholic fatty liver disease","volume":"24","author":"Lee","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2024072604373988600_bvae122-B16","doi-asserted-by":"crossref","first-page":"1232583","DOI":"10.1155\/2018\/1232583","article-title":"Effects of newer antidiabetic drugs on endothelial function and arterial stiffness: a systematic review and meta-analysis","volume":"2018","author":"Batzias","year":"2018","journal-title":"J. Diabetes Res"},{"key":"2024072604373988600_bvae122-B17","doi-asserted-by":"crossref","first-page":"110196","DOI":"10.1016\/j.intimp.2023.110196","article-title":"Semaglutide alleviates inflammation-induced endothelial progenitor cells injury by inhibiting MiR-155 expression in macrophage exosomes","volume":"119","author":"Pan","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"2024072604373988600_bvae122-B18","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.athplu.2022.05.004","article-title":"Semaglutide treatment attenuates vessel remodelling in ApoE-\/- mice following vascular injury and blood flow perturbation","volume":"49","author":"Jensen","year":"2022","journal-title":"Atheroscler Plus"},{"issue":"1","key":"2024072604373988600_bvae122-B19","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.pharep.2017.10.003","article-title":"Exenatide modulates metalloproteinase expression inhuman cardiac smooth muscle cells via the inhibition of Akt signaling pathway","volume":"70","author":"Gallego-Colon","year":"2018","journal-title":"Pharmacol Rep"},{"key":"2024072604373988600_bvae122-B20","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.atherosclerosis.2017.04.001","article-title":"Liraglutide, a GLP-1 receptor agonist, inhibits vascular smooth muscle cell proliferation by enhancing AMP-activated protein kinase and cell cycle regulation, and delays atherosclerosis in ApoE deficient mice","volume":"261","author":"Jojima","year":"2017","journal-title":"Atherosclerosis"},{"key":"2024072604373988600_bvae122-B21","doi-asserted-by":"crossref","first-page":"995007","DOI":"10.3389\/fendo.2022.995007","article-title":"Effects of semaglutide on vascular structure and proteomics in high-fat diet-induced obese mice","volume":"13","author":"Yue","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"7","key":"2024072604373988600_bvae122-B22","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.3390\/pharmaceutics15071945","article-title":"The effect of additional treatment with empagliflozin or semaglutide on endothelial function and arterial stiffness in subjects with type 1 diabetes mellitus-ENDIS study","volume":"15","author":"Navodnik","year":"2023","journal-title":"Pharmaceutics"},{"key":"2024072604373988600_bvae122-B23","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.peptides.2018.09.002","article-title":"Glucagon-like peptide-1 receptor action in the vasculature","volume":"111","author":"Almutairi","year":"2019","journal-title":"Peptides"},{"issue":"18","key":"2024072604373988600_bvae122-B24","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1161\/CIRCULATIONAHA.107.739938","article-title":"Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways","volume":"117","author":"Ban","year":"2008","journal-title":"Circulation"},{"issue":"6","key":"2024072604373988600_bvae122-B25","doi-asserted-by":"crossref","first-page":"E1209","DOI":"10.1152\/ajpendo.00237.2004","article-title":"Effects of glucagon-likepeptide-1 on endothelial function in type 2 diabetes patients with stable coronary arterydisease","volume":"287","author":"Nystrom","year":"2004","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"4","key":"2024072604373988600_bvae122-B26","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1210\/en.2018-00004","article-title":"GLP-1 receptor expression within the human heart","volume":"159","author":"Baggio","year":"2018","journal-title":"Endocrinology"},{"issue":"10","key":"2024072604373988600_bvae122-B27","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1007\/s00125-010-1831-8","article-title":"A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells","volume":"53","author":"Hattori","year":"2010","journal-title":"Diabetologia"},{"issue":"1-2","key":"2024072604373988600_bvae122-B28","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.mce.2010.04.022","article-title":"Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA- and PI3K\/Akt dependent pathways and requires GLP-1 receptor","volume":"325","author":"Erdogdu","year":"2010","journal-title":"Mol Cell Endocrinol"},{"issue":"2","key":"2024072604373988600_bvae122-B29","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jdiacomp.2016.10.001","article-title":"Incretin treatment and atherosclerotic plaque stability: role of adiponectin\/APPL1 signaling pathway","volume":"31","author":"Barbieri","year":"2017","journal-title":"J Diabetes Complications"},{"key":"2024072604373988600_bvae122-B30","doi-asserted-by":"crossref","first-page":"102849","DOI":"10.1016\/j.redox.2023.102849","article-title":"Effects of GLP-1 receptor agonists on mitochondrial function, inflammatory markers and leukocyte-endothelium interactions in type 2 diabetes","volume":"66","author":"Luna-Marco","year":"2023","journal-title":"Redox Biol"},{"issue":"10","key":"2024072604373988600_bvae122-B31","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1517\/14712598.2015.1067299","article-title":"Liraglutide improves carotid intima-media thickness in patients with type 2 diabetes and non-alcoholic fatty liver disease: an 8-month prospective pilot study","volume":"15","author":"Rizvi","year":"2015","journal-title":"Expert OpinBiol Ther"},{"issue":"1","key":"2024072604373988600_bvae122-B32","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1475-2840-13-49","article-title":"Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study","volume":"13","author":"Rizzo","year":"2014","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"2024072604373988600_bvae122-B33","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","article-title":"Semaglutide 2\u00b74mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial","volume":"8","author":"Loomba","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"12","key":"2024072604373988600_bvae122-B34","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"issue":"9","key":"2024072604373988600_bvae122-B35","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1111\/apt.16608","article-title":"Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging","volume":"54","author":"Flint","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"issue":"21","key":"2024072604373988600_bvae122-B36","doi-asserted-by":"crossref","first-page":"4673","DOI":"10.3390\/nu14214673","article-title":"Once-weekly subcutaneous semaglutide improves fatty liver disease in patients with type 2 diabetes: a 52-week prospective real-life study","volume":"14","author":"Volpe","year":"2022","journal-title":"Nutrients"},{"key":"2024072604373988600_bvae122-B37","doi-asserted-by":"crossref","first-page":"769069","DOI":"10.3389\/fendo.2021.769069","article-title":"Efficacy and safety of GLP-1 receptor agonists in patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"12","author":"Zhu","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"2024072604373988600_bvae122-B38","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis andmanagement of nonalcoholic fatty liver disease: practice guidancefrom the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"issue":"5","key":"2024072604373988600_bvae122-B39","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1002\/hep.23569","article-title":"Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway","volume":"51","author":"Gupta","year":"2010","journal-title":"Hepatology"},{"key":"2024072604373988600_bvae122-B40","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.diabres.2015.12.003","article-title":"Circulating adiponectin levels in type 2 diabetes mellitus patients with or without non-alcoholic fatty liver disease: results of a small, open-label, randomized controlled intervention trial in a subgroup receiving short-term exenatide","volume":"113","author":"Savvidou","year":"2016","journal-title":"Diabetes Res Clin Pract"},{"issue":"5","key":"2024072604373988600_bvae122-B41","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.3390\/biomedicines10051020","article-title":"Comparative transcriptome analysis reveals that exendin-4 improves steatosis in HepG2 cells by modulating signaling pathways related to lipid metabolism","volume":"10","author":"Errafii","year":"2022","journal-title":"Biomedicines"},{"key":"2024072604373988600_bvae122-B42","doi-asserted-by":"crossref","first-page":"602574","DOI":"10.3389\/fcell.2020.602574","article-title":"Liraglutide alleviates hepatic steatosis by activating the TFEB-regulated autophagy-lysosomal pathway","volume":"8","author":"Fang","year":"2020","journal-title":"Front Cell Dev Biol"},{"issue":"2","key":"2024072604373988600_bvae122-B43","doi-asserted-by":"crossref","first-page":"140","DOI":"10.4158\/EP11169.OR","article-title":"Clinical use of liraglutide in type 2 diabetes and its effects on cardiovascular risk factors","volume":"18","author":"Varanasi","year":"2012","journal-title":"Endocr Pract"},{"issue":"9","key":"2024072604373988600_bvae122-B44","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.3390\/antiox10091379","article-title":"Effects of a 12-month treatment with glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter-2 inhibitors, and their combination on oxidant and antioxidant biomarkers in patients with type 2 diabetes","volume":"10","author":"Lambadiari","year":"2021","journal-title":"Antioxidants (Basel)"},{"issue":"48","key":"2024072604373988600_bvae122-B45","doi-asserted-by":"crossref","first-page":"e23360","DOI":"10.1097\/MD.0000000000023360","article-title":"Usefulness of controlled attenuation parameter and liver stiffness measurement for detecting increased arterial stiffness in asymptomatic populations in China","volume":"99","author":"Yu","year":"2020","journal-title":"Medicine (Baltimore)"},{"issue":"10","key":"2024072604373988600_bvae122-B46","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1631\/jzus.B1400028","article-title":"Association between non-alcoholic fatty liver disease and arterial stiffness in the non-obese, non-hypertensive, and non-diabetic young and middle-aged Chinese population","volume":"15","author":"Yu","year":"2014","journal-title":"J Zhejiang Univ Sci B"},{"key":"2024072604373988600_bvae122-B47","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.atherosclerosis.2019.02.005","article-title":"Non-alcoholic fatty liver disease presence and severity are associated with aortic stiffness beyond abdominal obesity: the ELSA-brasil","volume":"284","author":"Harada","year":"2019","journal-title":"Atherosclerosis"},{"issue":"4","key":"2024072604373988600_bvae122-B48","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/hep4.1155","article-title":"Nonalcoholic fatty liver disease contributes to subclinical atherosclerosis: a systematic review and meta-analysis","volume":"2","author":"Zhou","year":"2018","journal-title":"Hepatol Commun"},{"issue":"3","key":"2024072604373988600_bvae122-B49","doi-asserted-by":"crossref","first-page":"454","DOI":"10.3390\/jpm12030454","article-title":"Sex differences in response to treatment with glucagon-like peptide 1 receptor agonists: opportunities for a tailored approach to diabetes and obesity care","volume":"12","author":"Rentzeperi","year":"2022","journal-title":"J Pers Med"},{"issue":"3","key":"2024072604373988600_bvae122-B50","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s13300-022-01360-7","article-title":"Semaglutide in obesity: unmet needs in men","volume":"14","author":"Jensterle","year":"2023","journal-title":"Diabetes Ther"}],"container-title":["Journal of the Endocrine Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/8\/8\/bvae122\/58644576\/bvae122.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/8\/8\/bvae122\/58644576\/bvae122.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T04:39:20Z","timestamp":1721968760000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jes\/article\/doi\/10.1210\/jendso\/bvae122\/7708198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,1]]},"references-count":50,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,7,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jendso\/bvae122","relation":{},"ISSN":["2472-1972"],"issn-type":[{"value":"2472-1972","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,8]]},"published":{"date-parts":[[2024,7,1]]},"article-number":"bvae122"}}